News | June 08, 2010

Clinical Images of Whole Body PET/MR Released at SNM 2010

Philips PET MRI Dual Systems low res

Philips Healthcare's PET/MR system is in clinical trials.

PET MRI Man Lo res

Some of the first clinical images from Philips' PET/MR system.

June 8, 2010 - A breakthrough in hybrid medical imaging that will provide data for advancing diagnosis of neurological disorders, oncological and cardiovascular diseases is becoming a reality.

At the Society of Nuclear Medicine (SNM) annual meeting, held in Salt Lake City, June 6 to 8, Philips Healthcare is showing clinical images of its positron emission tomography/magnetic resonance imaging (PET/MRI) system.

The clinical studies on display at Philips' booth were conducted using Philips’ investigational whole body PET/MRI imaging systems at the University of Geneva in Switzerland and Mount Sinai Medical Center in New York. These studies are designed to take advantage of the soft-tissue contrast capabilities of magnetic resonance imaging.

The hybrid PET/MRI scanner simultaneously delivers the anatomical and functional information, such as soft tissue contrast and physiological processes in blood vessels, achievable using MRI scanners and the molecular imaging information provided by PET. As a result, it would combine the best of both worlds, which could ultimately help to pinpoint and characterize disease sites within the body more accurately than is currently possible.

Philips' team of researchers announced in October of 2009 they had developed of a functional gamma-ray detector that meets the performance requirements of the latest time-of-flight PET scanners. The new gamma-ray detectors were designed to be compatible with the strong static and dynamic magnetic fields that would be present in a combined PET/MRI scanner.

For more information: www.philips.com/healthcare

 

Related Content

Artificial Intelligence Provides Faster, Clearer MRI Scans

A new artificial-intelligence-based approach to image reconstruction, called AUTOMAP, yields higher quality images from less data, reducing radiation doses for CT and PET and shortening scan times for MRI. Shown here are MR images reconstructed from the same data with conventional approaches, at left, and AUTOMAP, at right. Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital

News | Artificial Intelligence | July 17, 2018
A research team with funding from the National Institute for Biomedical Imaging and Bioengineering (NIBIB) has...
Researchers Trace Parkinson’s Damage in the Heart
News | PET Imaging | July 17, 2018
A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new therapies and...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
iSchemaView Brings RAPID Imaging Platform to Australia and New Zealand
News | Stroke | July 13, 2018
iSchemaView has signed Diagnostic Imaging Australia (DIA) to be the exclusive distributor for the RAPID cerebrovascular...
High-Strength MRI May Release Mercury from Amalgam Dental Fillings
News | Magnetic Resonance Imaging (MRI) | July 05, 2018
Exposure to ultra-high-strength magnetic resonance imaging (MRI) may release toxic mercury from amalgam fillings in...
Ensuring that the FMDS for MRI safety is mounted outside Zone IV provides maximum early warning.

Ensuring that the FMDS for MRI safety is mounted outside Zone IV provides maximum early warning. (Images courtesy of Metrasens)

Feature | Magnetic Resonance Imaging (MRI) | July 03, 2018 | By Tobias Gilk
Nearly every job in the country is subject to certain health and safety regulations. Construction workers must wear...
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
MILabs Introduces Futuristic PET Capabilities on New VECTor6 System
Technology | PET Imaging | June 28, 2018
At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in Philadelphia,...
Technology | Magnetic Resonance Imaging (MRI) | June 27, 2018
June 27, 2018 — Zetta Medical Technologies announced the release of Zoom, its latest...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
Overlay Init